PARP inhibitor (PARPi), immune checkpoint inhibitor (ICI), HER2/HER2-positive breast cancers (HER2+), triple negative breast cancers (TNBC), hereditary breast cancers driven by germline mutations in BRCA genes 1 or 2 (gmBRCA), hormone receptor-positive breast cancers (HR+), metastatic breast cancer (MBC) or early breast cancer (BC). This evidence concerns the gene NR4A1 and breast cancer.